US BioDefense makes cardiac regeneration pact:
This article was originally published in Clinica
Executive Summary
US BioDefense has formed a heart tissue regeneration deal with the University of Texas MD Anderson Cancer Center that gives it the priority option to review and license patent pending technology regarding the use of non-marrow stem cell for cardiac regeneration. "The use of these stem cells for myocardial regeneration may prove to be superior to other stem cell sources by circumventing the pain and anaesthesia complications associated with bone marrow aspiration procedures," said David Chin, CEO of the City of Industry, California-based firm.